HOME | PRESS RELEASES | HOW TO ORDER | CONTACT US | CAREERS | Japanese

Conference Presentations, Posters & Abstracts —
Recent Pharsight® Contributions


View Archive

 

2012


October

 

Mercier F. Model-based meta-analysis of lesion count time dynamics in multiple sclerosis. [poster presentation]. To be presented at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 10-13, 2012; Lyon, France.

 

September

 

Choi SL, Chanu P, Falcoz C, Monteleone M, Sinha V. A Literature-based Integrated Glucose-Insulin Model: Application to Evaluate Dose-Titration 114 Schemes for LY2605541 in a Phase 2 Trial. [poster PA8-1]. Presented at World Conference on Pharmacometrics (WCoP); September 5-7; Seoul, Korea.

 

June

 

Nixon R, Eckert B, Cutter G, Mercier F, Francis G, Kappos L. Indirect comparisons of oral fingolimod versus natalizumab and cladribine for the treatment of relapsing–remitting multiple sclerosis based on data from FREEDOMS, AFFIRM and CLARITY. [poster presentation]. Presented at European Neurological Society (ENS); June 9-12; Prague, Czech Republic.

 

The following was presented at the Annual Meeting of the Population Approach Group in Europe (PAGE); June 5-8, 2012; Venice, Italy.

 

Drug/Disease Modeling

Ribbing J, Falcoz C, Coreea I, Martin SW. Literature Model for FEV1 in COPD Trials – Separating the Dynamic Components of Placebo Effect, Disease Progression and Interacting Drug Effects. [oral presentation].

 

CNS, Infection, Oncology, Pediatrics

Ezzet F, Liang E, Wagg J, Cooney M, Abushakra S. Power Calculation Based on Pharmacokinetic Sampling Designs of ELND005 in a Phase 3 Clinical Trial Design in Mild Alzheimer Disease Patients. [poster presentation].


Claret L, Gupta M, Joshi A, Sarapa N, He J, Powell B, Bruno R. Evaluation of Tumor-Size Response Metrics to Predict Survival and Progression Free Survival in First-Line Metastatic Colorectal Cancer. [poster presentation].

 

Kassir N, Mouksassi MS, Gosselin N, Marier JF. A Modelling and Simulations Framework to Optimize Paediatric Studies and Facilitate Decision-Making. [poster presentation].

 

Estimation Methods

Mercier F, Claret L, Bruno R. A discussion on two approaches for indirect treatment comparisons based on public-domain metadata: The case of side-effects incidence. [poster presentation].

 

Leary RH, Dunlavey M. QRPEM, A Quasi-Random Parametric EM Method. [poster presentation].

 

Study Design

Liang E, Ezzet F, Wagg J, Cooney M, Abushakra S. Clinical Trial Design Optimization: A Pharmacokinetic Sampling Plan for a Phase 3 Clinical Trial in Mild Alzheimer Disease Patients. [poster presentation].

 

Gosselin NH, Mouksassi MS, Kassir N, Pheng LH, Marier JF. Simultaneous Optimization of Sampling Strategies for Parent and Metabolite Data Taking into Account a Body Weight Distribution: Applications to Paediatric Studies. [poster presentation].

 

Marchand M, Chenel M, Merdjan H, Mouksassi S. How to support a definitive bioequivalence study design using modeling and simulation. [poster presentation].

 

Other Modeling Applications

Falcoz C, Bozec S, Cravo D, Merdjan H, Bolze S. Population PKPD modeling of an anti-diabetic compound with a new mechanism of action in ob/ob mice to predict the human dose. [poster presentation].

 

Mouksassi S, Kassir N, Gosselin NH, Marier JF. Equivalence of locally acting drugs based on pharmacodynamic data: development of a novel 1 step method and use of trial simulations to assess sources of variability and power definitive studies. [poster presentation].

Chanu P, Gao X, Bruno R, Harnisch L. On the use of hemodynamics biomarkers to assess the benefit of high doses of sildenafil in some patients with pulmonary arterial hypertension (PAH). [poster presentation].

 

May

 

The following posters were presented at the American Thoracic Society International Conference; May 18-23, 2012; San Francisco, California.

 

Reisner C, Ferguson GT, St. Rose E, Thomas M, Vasilinin G, Marier JF, Orevillo CJ. Pearl Therapeutics' Combination LAMA/LABA MDI (GFF-MDI, PT003) Formulation Of Formoterol Fumarate And Glycopyrrolate Provides Similar Systemic Exposure To The Individual MDI Formulations Administered Alone In Patients With COPD Following 1-Week Dosing. [poster presentation].

 

Rose ES, Strom S, Fischer T, Vasilinin G, Golden M, Marier JF, Reisner C, Orevillo CJ. Pharmacokinetic (PK) Bioequivalence And Comparable Efficacy/Safety Were Demonstrated With Pearl Therapeutics' Formoterol Fumarate MDI (FF-MDI, PT005) Compared To Foradil® Aerolizer® In A Randomized, Double-Blind, Placebo-Controlled Study in Patients with COPD. [poster presentation].

 

Orevillo CJ, . Fogarty C, Dunn L, Parrino J, St. Rose E, Fernandez C, Covino B, Fischer T, Strom S, Vasilinin G, Marier JF, PhD, Reisner C. Pearl Therapeutics' Formoterol Fumarate MDI (FF-MDI, PT005) Demonstrates Pharmacokinetic Bioequivalence To Foradil® Aerolizer® In A Randomized, Double-Blind, Single Dose, Six-Treatment, Placebo-Controlled, Crossover Phase 2b Study in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). [poster presentation].

 

April

 

Li D, Selmaj K, Zhao G, Cheng Y, Mercier F, Rochotte E, Wallstrom E. MRI Findings of BOLD: A Phase 2 Dose-Finding Study Using Adaptive Design and Modeling Methods for BAF312 in Relapsing-Remitting MS. [oral presentation]. Presented at American Academy of Neurology (AAN) Annual Meeting; April 21-28; New Orleans, Louisiana.

 

March

 

Bruno R. Invited presentation on Oncology Drug-Disease Modeling Framework to Predict Clinical Endpoints, as part of workshop on "Should We Tolerate the Maximally Tolerated Dose for Targeted Anti-Cancer Agents?" Presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; March 12-17, 2012; National Harbor, Maryland.


Poland B. Decision Quality and Smart R&D Principles: Common Themes Across Industries. Invited presentation at ASoP/ASCPT Joint Pre-Conference, "Quantitative Decision Making in Development of Drugs/Biologics: What Can We Learn From Other Industries?"; March 13-14, 2012; National Harbor, Maryland.

 

Marier JF, Gosselin NH, Mouksassi MS, Kassir N, Yee S, Petersen C, Day W. POPULATION PK/PD MODELING OF VI-0521, A FIXED-DOSE COMBINATION PRODUCT OF IMMEDIATE-RELEASE PHENTERMINE AND CONTROLLED-RELEASE TOPIRAMATE FOR THE TREATMENT OF OBESITY. [poster presentation]. Presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; March 12-17, 2012; National Harbor, Maryland.

 

Marier JF, Kassir N, Mouksassi MS, Gosselin NH, Yee S, Petersen C, Day W. POPULATION PK MODELING OF IMMEDIATE-RELEASE PHENTERMINE AND MODIFIED-RELEASE TOPIRAMATE ADMINISTERED AS A FIXED-DOSE COMBINATION PRODUCT (VI-0521).[poster presentation]. Presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; March 12-17, 2012; National Harbor, Maryland.



Graham RA, Chang I, Jin JY, Wang B, Dufek MB, Ayache J, Ezzet F, Zerivitz K, Low J, Dresser MJ. DAILY DOSING OF VISOMODEGIB TO STEADY-STATE DOES NOT PROLONG THE QTc INTERVAL IN HEALTHY VOLUNTEERS. [poster presentation]. Presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; March 12-17, 2012; National Harbor, Maryland.

 

Marier JF, Jomphe C, McCauley TJ, Beliveau M. Pharmacokinetic and Pharmacodynamic (PK/PD) Correlation of Idursulfase in Cerebro Spinal Fluid (CSF) of Cynomolgus Monkeys after Intrathecal (IT) and Intravenous (IV) Administration. [poster presentation]. Presented at Society of Toxicology (SOT) Annual Meeting; March 11-15, 2012; San Francisco, California.

 

Jomphe C, McCauley TG, Marier JF, Beliveau M. Pharmacokinetics (PK) of Arylsufatase A and Idursulfase in Cynomolgus Monkeys Cerobro-Spinal Fluid (CSF) after Intrathecal (IT) Administration. [poster presentation]. Presented at Society of Toxicology (SOT) Annual Meeting; March 11-15, 2012; San Francisco, California.

 

McCauley TG, Jomphe C, Marier JF, Beliveau M. Pharmacokinetics (PK) of Arylsufatase A and Idursulfase in Cynomolgus Monkeys Serum after Intravenous (IV) Administration. [poster presentation]. Presented at Society of Toxicology (SOT) Annual Meeting; March 11-15, 2012; San Francisco, California.

 

Beliveau M, McCauley TG, Jomphe C, Marier JF. Sytemic and Central Nervous System (CNS) Distribution of Arylsufatase A and Idursulfase in Cynomolgus Monkeys after Intrathecal (IT) and Intravenous (IV) Administration. [poster presentation]. Presented at Society of Toxicology (SOT) Annual Meeting; March 11-15, 2012; San Francisco, California.

 

Poulin P, Tolomeo T, Lemire I, Leonard P, Marier JF, Beliveau M. Role of the Asialoglycoprotein Receptors in Predicting the Systemic Clearance of ENB-0040, a Human Recombinant Tissue Non-Specific Alkaline Phosphatase Currently Being Developed for the Treatment of Hypophosphatasia. [poster presentation]. Presented at Society of Toxicology (SOT) Annual Meeting; March 11-15, 2012; San Francisco, California.

 

 

2011


December

Bruno R, Jonsson F, Zaki M, Jacques C, Richardson P, Rajkumar SV, Claret L. [poster presentation]. Simulation of Clinical Outcome for Pomalidomide plus Low-Dose Dexamethasone in Patients With Refractory Multiple Myeloma Based on Week 8 M-Protein Response. [poster presentation]. Presented at: American Society of Hematology (ASH) Annual Meeting and Exposition; December 10-13, 2011; San Diego, California.

 

November

Reyderman L, Darpo B, Carrothers TJ, Kristensen A. Analysis of the concentration-QTc relationship for eribulin mesylate. [poster presentation]. Presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; November 12-16, 2011; San Francisco, California.

Liang E, Wagg J, Jonsson F, Cedarbaum J, Abushakra S. Correlations of Pharmacokinetic (PK) Measures to Pharmacodynamic (PD) Effects of ELND005 (Scyllo-inositol) from a Phase 2 Dose-Ranging Study in Mild to Moderate Alzheimer's Disease. [poster presentation]. Presented at: Clinical Trials on Alzheimer's Disease 4th Annual Conference; November 3-5, 2011; San Diego, California.


October

Miller B, Hershberger E, Chandorkar G, Friedland I, Umeh O, Mouksassi S, Fenneteau F, Marier JF. Probability of Target Attainment (PTA) of CXA-201 in Patients with Renal Hyperclearance. [poster presentation]. Presented at: 49th Annual Meeting of the Infectious Diseases Society of America (IDSA); October 20-23, 2011; Boston, Massachusetts.


September


Wagg J. Bridging Ethnic Factors in Pharmacometric Modeling and Simulation of Clinical Trials. [invited presentation]. Presented at: Kitasato-Harvard Symposium on Advanced and Global Drug Development; September 27-28; 2011; Tokyo, Japan.

Claret L, Jonsson F, Zaki M, Jacques C, Richardson P, Rajkumar VS, Bruno R. Simulation of clinical endpoints (survival, PFS) in patients with refractory multiple myeloma treated with pomalidomide based on interim week 8 M-protein response. [poster presentation]. Presented at: The European Multidisciplinary Cancer Congress; September 23-27, 2011; Stockholm, Sweden.

Claret L, Chanu P, Lindbom L, Stark FS, Gilberg F, Frey N, Bruno R. Clinical trial simulations to assess capecitabine dose reduction in combination with docetaxel in second line treatment of metastatic breast cancer. [poster presentation]. Presented at: The European Multidisciplinary Cancer Congress; September 23-27, 2011; Stockholm, Sweden

Miller B, Hershberger E, Mouksassi MS, Benziger DP, Steenbergen J, Fenneteau F, Marier JF, Friedland I. CXA-201 (CXA/TAZ) Dose Selection Based on Probability of Target Attainment (PTA) and Drug Exposure in Subjects with Varying Degrees of Renal Impairment (RI). [presentation]. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2011; Chicago, Illinois.

Marier JF. Target-Based Dosing Strategies of Monoclonal Antibodies:  Applications to Special Populations. [invited presentation]. Presented at: American College of Clinical Pharmacology (ACCP) Annual Meeting; September 11-13, 2011; Chicago, Illinois.

Carrothers TJ. Modeling and simulation of the exposure-QTc relationship: from preclinical to early clinical to the TQT study. [invited presentation]. Presented at: 2nd DIA Cardiac Safety Workshop in Japan; September 5-6, 2011; Tokyo, Japan.

Bax L. Contemporary Topics In Meta-analysis For Drug Development And Evaluation. [invited presentation]. Presented at: Japanese Conference on Pharmacometrics (JCoP); September 2-3, 2011; Tokyo, Japan.

July

 

Cedarbaum JM, Wagg JK. Predicting Initial Changes in Brain Volume with Effective Anti-Amyloid Agents: Just Ask Alice. [poster presentation]. Presented at: International Conference on Alzheimer's Disease (ICAD); July 16-21, 2011; Paris, France.

Liang E, Cedarbaum JM, Abushakra S, Green M, Yan L, Wagg JK. Population Pharmacokinetic Analysis of Plasma, Cerebrospinal Fluid, and Brain ELND005 in Patients with Mild to Moderate Alzheimer’s Disease. [poster presentation]. Presented at: International Conference on Alzheimer's Disease (ICAD); July 16-21, 2011; Paris, France.

June

Poland B, Kastrissios H, Gupta S, Stone J. Population Pharmacokinetic Analysis Finds No Clinically Important Effects of Demographic and Health Covariates on Boceprevir Exposure. [abstract driven presentation]. Presented at: 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; June 22-23, 2011; Boston, MA.

The following posters were presented at the Annual Meeting of the Population Approach Group in Europe (PAGE); June 7-10, 2011; Athens, Greece.

Pediatrics

Chanu P, Gao X, Smith M, Bruno R, Harnisch L. A dose selection rationale based on hemodynamics for sildenafil in pediatric patients with pulmonary arterial hypertension (PAH).

Methodology and Applications: Cardiovascular

Facius A, Claret L, Bruno R, Lahu G, Bredenbröcker D. Modelling and Simulation based Techniques to support Trial Design and Submission of Daxas.

Ezzet F, Correa I. Meta-Analysis of Antiplatelets in Patients with Atrial Fibrillation: A Survival Model.

Estimation Methods

Leary RH, Chittenden J, Dunlavey M, Matzuka B. Exact Reproducibility of Population PK/PD NLME Numerical Results across Different Computational Environments.

Chitenden J, Leary RH, Matzuka B, Dunlavey M. Evaluation of the Lindstrom-Bates FOCE Algorithm with Simulated Pharmacokinetic Datasets.

May

Harnisch LO, Chanu P, Gao X, Smith M, Bruno R. Hemodynamics As An Additional Measure To Prove Efficacy And To Provide A Dose Rationale For Sildenafil In Pediatric Patients With Pulmonary Arterial Hypertension (PAH). [poster presentation]. Presented at: American Thoracic Society (ATS) International Conference; May 13-18; Denver, Colorado.

Hershberger E, Mouksassi M, Steenbergen J, Benziger D, Fenneteau F, Marier JF. CXA-101/tazobactam probability of target attainment using population pharma-cokinetic analysis. [poster presentation]. Presented at: 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)/27th Intl. Congress of Chemotherapy (ICC); May 7-10, 2011; Milan, Italy.

Hershberger E, Benziger D, Pheng L, Trinh M, Marier JF. Pharmacokinetics of CXA-101/tazobactam in subjects with mild or moderate renal impairment. [poster presentation]. Presented at: 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)/27th Intl. Congress of Chemotherapy (ICC); May 7-10, 2011; Milan, Italy.

April

The following posters were presented at the American Conference on Pharmacometrics (ACoP); April 3-6, 2011; San Diego, CA.

PK/PD and Mechanistic Modeling

Fenneteau F, Kassir N, Mouksassi MS, Merdjan  H, Marier JF, Hershberger E, Benziger D. Population PK/PD Modeling and Simulations of a Fixed-Dose Combination of CXA 101 and Tazobactam to Optimize Dosing Strategies in Renal Impaired Patients With Complicated Urinary Tract Infection.

Prins NH, Green M, Haughie S, Johnson P, Martin SW. Use of Model Based Meta-Analysis Combining Patient-Level with Summary-Level Data Using Multilevel Random Effects to Provide a Quantitative Assessment of the Clinical Efficacy (IPSS) Profile and Competitive Positioning of a PDE5 Inhibitor (UK369,003).

Gupta M, Wang B, Carrothers TJ, Joshi A, LoRusso P, Chu W, Shih T, Loecke D, Girish S. Exposure-Response Analysis in Patients with HER2-positive (HER2+) Metastatic Breast Cancer (MBC) to Assess the Effect of T-DM1 on QTc Prolongation.

Gohore DG, Fenneteau F, Barrire O, Li J, Nekka F. Rational Drug Delineation: A Global Sensitivity Approach based on Therapeutic Tolerability to Deviations in Execution.

Special Populations - Pediatrics

Marier JF, Mouksassi MS, Gosselin NH, Breitmeyer J, Royal M. Application of Trial Simulations to Support Optimal Dosing of Intravenous Acetaminophen in Pediatric Patients: Regulatory Approval of the Product Based on a Minimum Number of Patients.

Mouksassi MS, Gosselin NH, Fenneteau F, Kassir N, Rich B, Marier JF. A Novel GAMLSS Model to Facilitate Simulations of Demographic Covariates in Special Populations: Selection of Realistic Covariates in Pediatric and Geriatric Patients in Clinical Trial Simulations to Optimize Dosing.

Smith MK, Harnisch L, Chanu P, Gao X, Bruno R. Hemodynamics as an Additional Measure to Prove Efficacy and to Provide a Dose Rationale for Sildenafil in Pediatric Patients With Pulmonary Arterial Hypertension (PAH).

Kassir N, Delaloye JR, Mouksassi MS, Lapeyraque AL, Labbe L, Alvarez F, Lallier M, Beaunoyer M, Theoret Y, Litalien C. An Optimal Sampling Strategy for Tacrolimus in Pediatric Liver Transplant Recipients Based on a Population Pharmacokinetic Model.

Clinical Applications - Antiviral

Poland B, Caro L, Green M, Nachbar B, Wenning L, Khan A, Wright H, Saltzman J, Stone J. Viral Dynamics Modeling and Simulation of the HCV Protease Inhibitor MK-7009 (Vaniprevir) with Peg-Interferon and Ribavirin.

Levi M, Frey N, Lemenuel A, Chanu P.Mechanistic Viral Kinetic (VK) modeling of a triple therapy for Hepatitis C: a protease inhibitor (Danoprevir) in combination with Pegasys® (PEG-IFN alpha-2a ) and Copegus® (Ribavirin).

Tools and Techniques

Mouksassi MS, Gosselin NH, Kassir N, Fenneteau F, Rich B, Marier JF. Cluster Analyses, Logistic Regressions, and Receiver Operator Characteristics (ROC) to Complement PK/PD Modeling: Case Studies for Immunomodulator, Anti-Depressive, and Anti-Diabetes Products.

Mouksassi MS, Beliveau M, Guinan E, Moore H, Gomeni R, Li X, Della Pasqua O, Weiner D, Hoke. Streamlining Pharmacometric Analyses Utilizing Multiple Data Management and Modeling Tools.

Bax L, Moons K, Satoh T, Carrothers TJ, Poland B. Graphical Assessments in Aggregate Level Meta-analysis; an Illustration with Clozapine Data.

Poland B. Extending Clinical Utility Analyses to Economic Decision Analyses.

Ezzet F. Literature Data Survival Models: Case Studies for Anticoagulants in Atrial Fibrillation and Acute Coronary Syndrome.

Chittenden J. Estimating a Time-Variant Pharmacokinetic Parameter as a Random Process.

Leary RL, Dunlavey M. QRPEM, A Quasi-random Parametric EM Method for PK/PD NLME Estimation.

March

Royal MA, Marier JF, Ang R, Pan C, Breitmeyer JB. IV Acetaminophen Dosing Simulations in Neonates and Infants. [poster presentation]. Presented at American Society of Pediatric Anesthesiology Meeting; March 31 - April 3, 2011; San Diego, California.

Poland B. When Pharmacometrics is Not Enough: Incorporating Utility and Economic Modeling. Invited oral presentation, as part of panel on 'Extending Pharmacometrics to Strategic Decisions.' Presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; March 2-5, 2011; Dallas, Texas.

Kassir N, Savant I, Mouksassi MS, Marier JF, Zhu W, Lau H. POPULATION PK AND EXPOSURE-RESPONSE ANALYSES OF APREMILAST IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS. [poster presentation].  Presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; March 2-5, 2011; Dallas, Texas.

Gosselin NH, Hsu CP, Mouksassi MS, Lu JF. POPULATION PHARMACOKINETIC (PK) MODELING OF CONATUMUMAB (CON) IN CANCER PATIENTS (PTS). [poster presentation]. Presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; March 2-5, 2011; Dallas, Texas.

Marier JF, Beliveau M, Stewart A, Jhee S, Ereshefsky L, Yen M, Moran S, Kim E, Fox A, Morimoto B. DAVUNETIDE PHARMACOKINETICS IN PLASMA AND CSF OF ALZHEIMER’S PATIENTS AND HEALTHY VOLUNTEERS. [poster presentation]. Presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; March 2-5, 2011; Dallas, Texas.

Marier JF, Trinh MM, Pheng LH, Mouksassi MS, Benziger D. POPULATION PK ANALYSIS OF INTRAVENOUS CXA-101 IN SUBJECTS WITH COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS. [poster presentation]. Presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; March 2-5, 2011; Dallas, Texas.

Gupta M, Wang B, Carrothers T, Joshi A, LoRusso PM, Chu W, Shih T, Loecke D, Girish S. EXPOSURE-RESPONSE ANALYSIS IN PATIENTS WITH HER2-POSITIVE (HER2+) METASTATIC BREAST CANCER (MBC) TO ASSESS THE EFFECT OF T-DM1 ON QTC PROLONGATION. [poster presentation]. Presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; March 2-5, 2011; Dallas, Texas.

Hammer G, Yaster M, Royal MA, Marier JF, Gosselin NH, Mouksassi S, Ang R, Hardalo C, Pan C, Breitmeyer JB. IV Acetaminophen Dosing Simulations in Neonates and Infants. [poster presentation]. Presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; March 2-5, 2011; Dallas, Texas.

Dart R, Cantrell L, Offerman SR, Heard K, Krenzelok EP, Rumack B, Gosselin NH, Mouksassi S, Marier JF, Hardalo C, Breitmayer JB, Royal MA. IV Acetaminophen Overdose Simulations: Guidance for Making Decisions on Early Treatment of IV Overdoses. [poster presentation]. Presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; March 2-5, 2011; Dallas, Texas.

Jomphe C, Lemire I, Leonard P, Reimer MJ, Beliveau M. Species-Specific Factors when Predicting Systemic Clearance in Rabbits via an Allometic Scaling Approach. [poster presentation]. Presented at: Society of Toxicology (SOT) Annual Meeting; March 6-10, 2011; Washington, DC.

February

Wagg J. Population Pharmacokinetics and PK-PD Correlation. [invited presentation]. Presented at: Applied Pharmaceutical Analysis - India 2011; February 6-9, 2011; Hyderabad, India.

 

Archive

2010

2009

2008

2007

2006

2005